Extended Data Fig. 7: GNE-7883 overcomes intrinsic and acquired sotorasib-resistance in NCI-H358 model in vivo.
(a) Growth contrast plot comparing growth rates (point estimate ± 95% confidence interval) of NCI-H358-R tumors treated with the indicated compounds. n = 8 animals per group. (b) Fitted NCI-H358-R tumor volume estimates are shown alongside tumor measurement of individual animals (n = 7 mice per group) over time. Dashed blue lines in the three right plots represent the fitted tumor growth curve under sotorasib treatment. (c) Percent changes in body weight of NCI-H358-R tumor-bearing mice (n = 7 mice per group) treated with indicated compounds over time. (d) Growth contrast plot comparing growth rates (point estimate ± 95% confidence interval) of NCI-H358-P tumors treated with the indicated compounds. The difference was statistically significant between sotorasib + GNE-7883 combo and sotorasib single agent (Dunnett’s test). (e) Fitted NCI-H358-P tumor volume estimates are shown alongside tumor measurement of individual animals (n = 10 mice per group) over time. Dashed blue lines in the three right plots represent the fitted tumor growth curve under vehicle treatment. (f) Percent changes in body weight of NCI-H358 xenograft tumor-bearing mice (n = 10 mice per group) treated with indicated compounds over time.
